Log in to save to my catalogue

Concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with...

Concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_dcfd0deb564b49aea3ec6f5cf657c6a6

Concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder: results from phase II study, BTCRC-GU15-023

About this item

Full title

Concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder: results from phase II study, BTCRC-GU15-023

Publisher

England: BMJ Publishing Group Ltd

Journal title

Journal for immunotherapy of cancer, 2023-02, Vol.11 (2), p.e006551

Language

English

Formats

Publication information

Publisher

England: BMJ Publishing Group Ltd

More information

Scope and Contents

Contents

BackgroundPatients with bladder cancer (BC) who are cisplatin ineligible or have unresectable disease have limited treatment options. Previously, we showed targeting programmed death-ligand 1 (PD-L1) with durvalumab (durva) and radiation therapy (RT) combination was safe in BC. We now report results from a phase II study evaluating the toxicity and...

Alternative Titles

Full title

Concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder: results from phase II study, BTCRC-GU15-023

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_dcfd0deb564b49aea3ec6f5cf657c6a6

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_dcfd0deb564b49aea3ec6f5cf657c6a6

Other Identifiers

ISSN

2051-1426

E-ISSN

2051-1426

DOI

10.1136/jitc-2022-006551

How to access this item